Canada OKs Celltrion's biosimilar

Korea Biomedical Review

10 September 2019 - Celltrion said that Health Canada has given the go-ahead for Herzuma (trastuzumab), an anticancer antibody biosimilar, in treating breast and gastric cancer.

The Canadian authorities approved the drug after validating the comprehensive data from nonclinical and clinical trials, which demonstrated that the safety and efficacy of Herzuma for treating breast and gastric cancer were comparable to the original drug.

Read Korea Biomedical Review article

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Outcome , Medicine , Canada , Biosimilar